Eudragit RS 100

Known as: Eudragit RS100 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2018
024619982018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Nano-drug delivery systems are being widely explored to overcome the challenges with existing antibiotics to treat bacterial… (More)
Is this relevant?
2013
2013
In the present study, an effort was made to develop the Eudragit RS100 based nanoparticulate system for sustained delivery of an… (More)
Is this relevant?
2012
2012
PURPOSE The purpose of this work was to preparation of vancomycin (VCM) biodegradable nanoparticles to improve the intestinal… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2011
2011
In this paper, we present in vitro and in vivo release data on pH-sensitive microspheres of Eudragit L100, Eudragit RS100 and… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
2011
2011
A controlled release resinate beads of betahistine diHCl (BHCl), a short half-life freely water soluble drug, was developed to… (More)
Is this relevant?
2009
2009
The investigation was concerned with design and characterization of oral controlled release matrix tablets of Zidovudine (AZT) in… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2008
2008
A ruman bypass delivery system was investigated to improve the delivery efficiency of L-carnitine in biological samples of cows… (More)
Is this relevant?
2007
2007
To investigate the anti-inflammatory impacts of piroxicam nanosuspension, in the current investigation, piroxicam:Eudragit RS100… (More)
Is this relevant?
2001
2001
Solid dispersions of diflunisal (DIF) with Eudragit RS100 (RS) and RL100 (RL) with different drug-to-polymer ratios were prepared… (More)
Is this relevant?
1998
1998
A microparticulate dosage form for a highly soluble drug, diltiazem hydrochloride, was formulated with Eudragit RS100 and RL100… (More)
Is this relevant?